- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03737474
A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder
June 29, 2021 updated by: Otsuka Pharmaceutical Co., Ltd.
A Multi-center, Open-label Trial to Assess the Long-term Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in Patients With Major Depressive Disorder
This trial is a 52-week study to assess the safety of long-term use of brexpiprazole as adjunctive therapy in combination with an antidepressant.
Study Overview
Study Type
Interventional
Enrollment (Actual)
248
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Shirakawa, Japan
- Nanko-kokorono clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Rollover subjects
- Outpatients
- Subjects who have completed the double-blind period of the double-blind trial and can commence the treatment period of this trial within 28 days from the completionof the double-blind period of the double-blind trial
- Subjects who have a level of comprehension sufficient to allow them to give written informed consent to all of the observation/examination/evaluation items specified in the protocol, and who can understand the contents of the trial
- Subjects with a DSM-5 classification-based diagnosis of "major depressive disorder, single episode" or "major depressive disorder, recurrent episode"
New subjects
- Outpatients
- Male and female patients ≥ 65 years of age (at the time of informed consent)
- Subjects who have a level of comprehension sufficient to allow them to give written informed consent to all of the observation/examination/evaluation items specified in the protocol, and who can understand the contents of the trial
- Patients with a DSM-5 classification-based diagnosis of "major depressive disorder, single episode" or "major depressive disorder, recurrent episode" whose current episode has persisted for at least 8 weeks
Exclusion Criteria:
Rollover subjects
- Female subjects who are pregnant or breastfeeding or who have positive pregnancy test (urine) results at baseline
- Sexually active male subjects or sexually active female subjects of childbearing potential, who will not agree to practice 2 different methods of birth control or to remain abstinent during the trial and for 30 days after the final IMP administration. For birth control, 2 of the following methods must be used: vasectomy, tubal ligation, vaginal diaphragm, intra-uterine contraceptive device (IUD), oral contraceptives, or condom with spermicide.
- Subjects who experience a change to the manic state in the antidepressant treatment period of the double-blind trial
- Subjects who are discovered to not meet the inclusion criteria or to fall under any of the exclusion criteria in the doubleblind trial
- Subjects who showed marked noncompliance with the IMP treatment in the double-blind trial (subjects whose IMP compliance rates are < 65% between prescribed visits)
New subjects
- Sexually active male subjects who will not agree to practice 2different methods of birth control or to remain abstinent during the trial and for 30 days after the final IMP administration. For birth control, 2 of the following methods must be used: vasectomy, tubal ligation, vaginal diaphragm, intra-uterine contraceptive device (IUD), oral contraceptives, or condom with spermicide.
- Patients with a treatment history showing that all antidepressants (also including those not used for the current major depressive episode) cannot be tolerated
- Patients with a history of electroconvulsive therapy
Patients with a diagnosis of any of the following diseases according to DSM-5
- Neurocognitive disorders
- Schizophrenia spectrum and other psychotic disorders
- Bipolar and related disorders
- Feeding and eating disorders
- Obsessive-compulsive disorder
- Panic disorder
- Posttraumatic stress disorder
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Brexpiprazole
2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily
|
2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The frequency of Adverse Events
Time Frame: From baseline to week 52
|
The incidence of the following events will be summarized: •Adverse events occurring after initiation of Interventional Medicinal Product administration |
From baseline to week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean changes from baseline in Montgomery Åsberg Depression Rating Scale(MADRS) at Week 52.
Time Frame: Baseline and Week 52
|
The proportion of subjects who decrease MADRS total scores more than 50%.
Reaction Rate and Remission Rate.The MADRS consists of 10 items assessing apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thought.
Each item is scored from 0 to 6, with higher scores indicating worse condition.
|
Baseline and Week 52
|
The proportion of subjects who score 1 or 2 on the Clinical Global Impression-Improvement(CGI-I) scale at Week 52
Time Frame: Baseline and Week 52
|
The CGI-I Scale is a clinician-rated scale which assesses the total improvement of the patient's condition compared to that at baseline.
Scores range from 0 to 7: 0 = Not assessed, 1= Very much improved, 2 = Much improved, 3= Minimally improved, 4= No change, 5= Minimally worse, 6= Much worse, 7= Very much worse.
Higher scores indicate worse condition.
|
Baseline and Week 52
|
Mean changes from baseline in Clinical Global Impression-Severity of illness(CGI-S) at Week 52
Time Frame: Baseline and Week 52
|
The CGI-S Scale is a clinician-rated scale which assesses how mentally ill the patient is at the time.
Scores range from 0 to 7: 0 = Not assessed, 1= Normal, not at all ill, 2 =Borderline mentally ill, 3= Mildly ill, 4= Moderately ill, 5= Markedly ill, 6= Severely ill, 7= Among the most extremely ill patients.
Higher scores indicate worse condition.
|
Baseline and Week 52
|
Mean changes from baseline in Hamiliton Depression Rating Scale(HAM-D) item total scores at Week 52
Time Frame: Baseline and Week 52
|
The HAM-D is a clinician-rated scale which evaluates the level of depression.
The HAM-D consists of 17 items such as depression mood, feeling of guilt, suicide, insomnia, work and activities, retardation, and so on.
Each item is scored from 0 to 2, 3 or 4, with higher scores indicating worse condition.
Summed subscales are combined to compute a total score.
Total score ranges from 0 to 53 , with higher score indicating worse condition.
|
Baseline and Week 52
|
Mean changes from baseline in Sheehan Disability Scale (SDS) scores at Week 52
Time Frame: Baseline and Week 52
|
SDS Scale is a patient-rated scale which assesses the degree of impairment for each of 3 items ("work/school," "social life," and "family life/home responsibilities") on a 11-point scale ranging from 0 to 10 and the number of "days lost" and "days unproductive" caused by in the past week.
|
Baseline and Week 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 4, 2018
Primary Completion (ACTUAL)
March 17, 2021
Study Completion (ACTUAL)
April 13, 2021
Study Registration Dates
First Submitted
July 29, 2018
First Submitted That Met QC Criteria
November 7, 2018
First Posted (ACTUAL)
November 9, 2018
Study Record Updates
Last Update Posted (ACTUAL)
July 1, 2021
Last Update Submitted That Met QC Criteria
June 29, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 331-102-00059
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.
IPD Sharing Time Frame
Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication.
There is no end date to the availability of the data.
IPD Sharing Access Criteria
Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software.
Research requests should be directed to clinicaltransparency@Otsuka-us.com.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Brexpiprazole
-
Otsuka Pharmaceutical Co., Ltd.Withdrawn
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAcute SchizophreniaKorea, Republic of, United States, Serbia, Ukraine, Romania, Poland, Canada, Latvia, Japan
-
Otsuka Pharmaceutical Co., Ltd.CompletedHealthy Adult MaleJapan
-
H. Lundbeck A/SOtsuka Pharmaceutical Co., Ltd.Terminated
-
Otsuka Pharmaceutical Development & Commercialization...H. Lundbeck A/STerminated
-
Otsuka Pharmaceutical Co., Ltd.Recruiting
-
Otsuka Pharmaceutical Development & Commercialization...H. Lundbeck A/SCompletedNervous System Diseases | Alzheimer's Disease | Mental Disorder | Agitation Associated With | Alzheimer's TypeFrance, United States, Bulgaria, Slovenia, United Kingdom, Russian Federation, Ukraine, Finland, Canada
-
Otsuka Pharmaceutical Development & Commercialization...H. Lundbeck A/SCompleted
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaUnited States
-
Otsuka Pharmaceutical Development & Commercialization...H. Lundbeck A/SCompletedIrritability Associated With Autism Spectrum Disorder (ASD)United States